Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 19, 2023 - Issue
Submit an article Journal homepage
353
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma

Jinpeng Li1 Intervention Ward 1, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, People’s Republic of ChinaCorrespondence[email protected]
View further author information
,
Yuntao Jia1 Intervention Ward 1, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, People’s Republic of ChinaView further author information
,
Changdong Shao2 Qixia Hospital of Traditional Chinese Medicine Hospital, Qixia, Shandong, People’s Republic of ChinaView further author information
,
Yuanming Li3 Laizhou Hospital of Traditional Chinese Medicine, Laizhou, People’s Republic of ChinaView further author information
&
Jinlong Song1 Intervention Ward 1, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, People’s Republic of ChinaView further author information
Pages 329-339 | Received 09 Dec 2022, Accepted 19 Mar 2023, Published online: 05 Apr 2023

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (3)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.